聚乙二醇干扰素α-2a治疗后HBeAg阴性慢性乙型肝炎患者早期血

StephenW

Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a

    Minghui Li, Lu Zhang, Yao Lu, Qiqi Chen, Huihui Lu, Fangfang Sun, Zhan Zeng, Gang Wan, Linqing Zhao & Yao Xie

Virologica Sinica (2020)Cite this article

    45 Accesses

    Metrics details

Abstract

Hepatitis B surface antigen (HBsAg) loss is an ideal treatment endpoint for patients with chronic hepatitis B (CHB). We investigated the predictive value of on-treatment HBsAg levels for HBsAg loss in hepatitis B e antigen (HBeAg)-negative CHB patients who received 120-week PEG-IFNα-2a treatment. Serum HBV DNA, HBsAg, and anti-HBs levels were assayed at baseline and every 3 months during the treatment. Of 81 patients, 12 achieved HBsAg loss, 20 achieved HBsAg < 100 IU/mL, and 49 maintained HBsAg ≥ 100 IU/mL. HBsAg loss rate was only 3.7% at 48 weeks, while it reached to 11.1% and 14.8% after treatment of 96 weeks and 120 weeks. The cutoff HBsAg levels at 12 weeks predicting HBsAg loss at 96 weeks and 120 weeks of treatment were 400 IU/mL and 750 IU/mL, with AUC 0.725 and 0.722, positive predictive value (PPV) 29.41% and 30.56%, and negative predictive value (NPV) 93.75% and 97.78%, respectively. The cutoff HBsAg levels at 24 weeks predicting HBsAg loss at 96 weeks and 120 weeks of treatment were 174 IU/mL and 236 IU/mL respectively, with AUC 0.925 and 0.922, PPV 40.0% and 46.15%, and both NPV 100%. The predictive ability of the cutoff HBsAg levels at 24 weeks was better than that at 12 weeks for HBsAg loss at either 96 or 120 weeks (χ2 = 3.880, P = 0.049 and χ2 = 4.412, P = 0.036). These results indicate that extended therapy is critical to HBsAg loss in HBeAg-negative CHB patients during PEG-IFN treatment, and the HBsAg level at 24 weeks can be used to predict HBsAg loss during tailoring PEG-IFN therapy.

StephenW

聚乙二醇干扰素α-2a治疗后HBeAg阴性慢性乙型肝炎患者早期血清HBsAg动力学可预测HBsAg丢失

    李明慧，张璐，陆瑶，陈启琦，陆慧慧，孙芳芳，曾增，万刚，赵林青＆谢瑶

Virologica Sinica（2020）援引本文

    45次访问

    指标详细信息

抽象

乙型肝炎表面抗原（HBsAg）丢失是慢性乙型肝炎（CHB）患者的理想治疗终点。我们调查了接受120周PEG-IFNα-2a治疗的乙型肝炎e抗原（HBeAg）阴性的CHB患者治疗中HBsAg水平对HBsAg丢失的预测价值。在治疗初期和治疗后每3个月检测一次血清HBV DNA，HBsAg和抗HBs水平。在81例患者中，有12例达到HBsAg丢失，20例达到HBsAg <100 IU / mL，49例维持HBsAg≥100 IU / mL。 HBsAg丢失率在48周时仅为3.7％，而在治疗96周和120周后分别达到11.1％和14.8％。预测在治疗96周和120周时HBsAg丧失的12周时HBsAg截止水平为400 IU / mL和750 IU / mL，AUC为0.725和0.722，阳性预测值（PPV）为29.41％和30.56％，阴性预测为价值（NPV）分别为93.75％和97.78％。预测治疗96周和120周时HBsAg丧失的24周时HBsAg截止水平分别为174 IU / mL和236 IU / mL，AUC为0.925和0.922，PPV为40.0％和46.15％，两者均为NPV 100％。在第96周或第120周时，HBsAg丧失的临界值在24周时的预测能力要好于在第12周时的预测能力（χ2= 3.880，P = 0.049，χ2= 4.412，P = 0.036）。这些结果表明，延长治疗对于PEG-IFN治疗期间HBeAg阴性CHB患者的HBsAg丢失至关重要，并且在调整PEG-IFN治疗期间24周的HBsAg水平可用于预测HBsAg丢失。

newchinabok

目前屈指可数的免疫药试验效果不好怎么办，你们觉得能绕过干挠素吗？你们觉得磕核苷药能长治久安吗？如果能够长治久安，还需研究新药干嘛？